Black Health
SSRI Depression Generalized anxiety disorder

Escitalopram (Lexapro) and Black patients

Brand names: Lexapro

Last reviewed: Sources checked:

What Escitalopram does

Escitalopram is the S-enantiomer of citalopram. It is one of the best-tolerated SSRIs and has a simpler dosing schedule (10 mg starting, 20 mg max) with fewer drug-drug interactions than sertraline or fluoxetine. It is a common first-choice SSRI in primary care.

What the evidence says for Black patients

The STAR*D and CO-MED trials enrolled reasonable numbers of Black participants (~18 percent in STAR*D). Remission rates with citalopram (closely related to escitalopram) were slightly lower in Black participants, but the gap largely disappeared after controlling for socioeconomic confounders and concomitant comorbidities (Trivedi et al., NEJM 2006;354:1243–52).

CYP2C19 pharmacogenomics apply similarly to escitalopram. Poor metabolizers may need 50 percent dose reductions; ultra-rapid metabolizers may need higher doses or a different SSRI. CPIC dosing guidance is available (Hicks et al., 2015).

As with sertraline, access and continuation gaps drive Black patient outcomes more than efficacy differences. Early follow-up, culturally-appropriate counseling, and side-effect monitoring are the high-value interventions.

Common alternatives

Sertraline, fluoxetine, or bupropion are reasonable alternatives. Duloxetine (Cymbalta) is an SNRI used when chronic pain coexists with depression.

Side effects

  • Nausea, GI upset early on
  • Sexual dysfunction
  • Sleep disturbance or vivid dreams
  • QT prolongation — avoid doses above 20 mg especially with other QT-prolonging drugs
  • Hyponatremia
  • Serotonin syndrome with MAOIs, triptans
  • Discontinuation syndrome
  • Boxed warning — suicidality in young adults

Factors that affect adherence

Generic escitalopram is inexpensive. The once-daily dose and generally milder side-effect profile compared to sertraline makes it easier to continue. 2-week and 6-week follow-up calls measurably reduce early discontinuation.

Questions to ask your doctor

Bring this list to your next appointment.

  • Should we stay at 10 mg or move to 20 mg if response is partial?
  • Are there drugs I'm taking that can interact (especially QT-prolonging)?
  • How long should I stay on this after I feel better?
  • Is therapy available and covered?

References

  1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D. NEJM. 2006;354:1243–1252.
  2. Hicks JK, Bishop JR, Sangkuhl K, et al. CPIC guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing. Clin Pharmacol Ther. 2015;98:127–134.
  3. U.S. Food and Drug Administration. Lexapro (escitalopram oxalate) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021323s047lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.